TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Multicenter, Randomized, Double-blind, Placebo-controlled Study of Darbepoetin Alfa for the Treatment of Anemia of Cancer
Brief Summary: The purpose of this study is to evaluate the efficacy of darbepoetin alfa versus placebo in reducing the occurrences of red blood cell transfusions in subjects with anemia of cancer who are not receiving chemotherapy.


Options:
A: Intervention Type: DRUG; Name: epoetin alfa; Assigned to Arm(s): N/A
B: Arm Label: Darbepoetin alfa; Type: EXPERIMENTAL; Interventions: Drug: Darbepoetin alfa | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo | Intervention Type: DRUG; Name: Darbepoetin alfa; Assigned to Arm(s): Darbepoetin alfa
C: Arm Label: Darbepoetin alfa - Group A; Type: EXPERIMENTAL; Interventions: Drug: Darbepoetin alfa | Arm Label: Placebo- Group B; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Darbepoetin alfa; Assigned to Arm(s): Darbepoetin alfa - Group A | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo- Group B
D: Arm Label: Darbepoetin alfa 6.75 mcg/kg Q4W; Type: EXPERIMENTAL; Interventions: Drug: Darbepoetin Alfa | Arm Label: Placebo Q4W; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Darbepoetin Alfa; Assigned to Arm(s): Darbepoetin alfa 6.75 mcg/kg Q4W | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo Q4W

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Multicenter, Randomized, Double-blind, Placebo-controlled Study of Darbepoetin Alfa for the Treatment of Anemia of Cancer
Brief Summary: The purpose of this study is to evaluate the efficacy of darbepoetin alfa versus placebo in reducing the occurrences of red blood cell transfusions in subjects with anemia of cancer who are not receiving chemotherapy.


Options:
A: Arm Label: Darbepoetin alfa; Type: EXPERIMENTAL; Interventions: Drug: Darbepoetin alfa | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo | Intervention Type: DRUG; Name: Darbepoetin alfa; Assigned to Arm(s): Darbepoetin alfa
B: Intervention Type: DRUG; Name: Epoetin alfa; Assigned to Arm(s): N/A
C: Intervention Type: DRUG; Name: epoetin alfa; Assigned to Arm(s): N/A
D: Arm Label: Darbepoetin alfa 6.75 mcg/kg Q4W; Type: EXPERIMENTAL; Interventions: Drug: Darbepoetin Alfa | Arm Label: Placebo Q4W; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Darbepoetin Alfa; Assigned to Arm(s): Darbepoetin alfa 6.75 mcg/kg Q4W | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo Q4W

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomized, Double-Blind, Placebo-Controlled Study to Determine the Efficacy and Safety of Epoetin Alfa in Critically Ill Subjects
Brief Summary: Erythropoietin (EPO) is a hormone produced in the kidney. Its function is to stimulate the production of red cells in the bone marrow. The purpose of this research study is to demonstrate that the administration EPO to critically ill subjects in the intensive care unit (ICU) reduces the number of patients requiring red blood cell (RBC) transfusion as compared with placebo (a liquid without active medicine).


Options:
A: Intervention Type: DRUG; Name: Epoetin alfa; Assigned to Arm(s): N/A
B: Intervention Type: DRUG; Name: Epoetin Alfa; Assigned to Arm(s): N/A
C: Arm Label: Darbepoetin alfa; Type: EXPERIMENTAL; Interventions: Drug: Darbepoetin alfa | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo | Intervention Type: DRUG; Name: Darbepoetin alfa; Assigned to Arm(s): Darbepoetin alfa
D: Intervention Type: DRUG; Name: epoetin alfa; Assigned to Arm(s): N/A

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomized, Double-Blind, Placebo-Controlled Study to Determine the Efficacy and Safety of Epoetin Alfa in Critically Ill Subjects
Brief Summary: Erythropoietin (EPO) is a hormone produced in the kidney. Its function is to stimulate the production of red cells in the bone marrow. The purpose of this research study is to demonstrate that the administration EPO to critically ill subjects in the intensive care unit (ICU) reduces the number of patients requiring red blood cell (RBC) transfusion as compared with placebo (a liquid without active medicine).


Options:
A: Arm Label: EPO; Type: EXPERIMENTAL; Interventions: Drug: EPOETINE ALPHA | Arm Label: Control; Type: ACTIVE_COMPARATOR; Interventions: Other: Control arm | Intervention Type: DRUG; Name: EPOETINE ALPHA; Assigned to Arm(s): EPO | Intervention Type: OTHER; Name: Control arm; Assigned to Arm(s): Control
B: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: EPO | Arm Label: 2; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DRUG; Name: EPO; Assigned to Arm(s): 1
C: Arm Label: EPO; Type: EXPERIMENTAL; Interventions: Drug: Darbepoetin alfa | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Darbepoetin alfa; Assigned to Arm(s): EPO | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
D: Intervention Type: DRUG; Name: Epoetin alfa; Assigned to Arm(s): N/A

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomized Trial to Evaluate 2 Hours of Daily Patching for Amblyopia in Children 3 to <7 Years Old
Brief Summary: The objectives of the Spectacle Phase are:

* In previously untreated pure anisometropic patients (i.e. patients who have not used spectacles in the last year and who do not have strabismus), to determine

  1. the incidence of resolution of amblyopia with spectacle correction alone and
  2. the time course of visual acuity improvement with spectacle correction alone.
* In all other patients, to achieve maximal improvement with spectacle correction prior to entering the randomized trial.

The objectives of the Randomized Trial are:

* To determine whether 5 weeks of patching treatment (2 hours of patching per day of the sound eye combined with at least one concurrent hour of near activities), compared with a control group (using spectacle correction only), improves visual acuity in patients with moderate to severe amblyopia (20/40 to 20/400).
* To determine the maximal improvement and time course of improvement with this patching treatment regimen.


Options:
A: Arm Label: Patching; Type: ACTIVE_COMPARATOR; Interventions: Device: Eye Patch | Arm Label: Atropine; Type: ACTIVE_COMPARATOR; Interventions: Drug: Atropine | Intervention Type: DRUG; Name: Atropine; Assigned to Arm(s): Atropine | Intervention Type: DEVICE; Name: Eye Patch; Assigned to Arm(s): Patching
B: Arm Label: Near activities; Type: ACTIVE_COMPARATOR; Interventions: Device: Eye Patch, Procedure: Near activities | Arm Label: Distance activities; Type: ACTIVE_COMPARATOR; Interventions: Device: Eye Patch, Procedure: Distance activities | Intervention Type: DEVICE; Name: Eye Patch; Assigned to Arm(s): Distance activities, Near activities | Intervention Type: PROCEDURE; Name: Near activities; Assigned to Arm(s): Near activities | Intervention Type: PROCEDURE; Name: Distance activities; Assigned to Arm(s): Distance activities
C: Arm Label: Atropine; Type: ACTIVE_COMPARATOR; Interventions: Drug: Atropine | Arm Label: Atropine plus plano; Type: ACTIVE_COMPARATOR; Interventions: Drug: Atropine, Device: Plano Lens | Intervention Type: DRUG; Name: Atropine; Assigned to Arm(s): Atropine, Atropine plus plano | Intervention Type: DEVICE; Name: Plano Lens; Assigned to Arm(s): Atropine plus plano
D: Intervention Type: DEVICE; Name: Eye patch; Assigned to Arm(s): N/A | Intervention Type: DEVICE; Name: Spectacles; Assigned to Arm(s): N/A

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomized Trial to Evaluate 2 Hours of Daily Patching for Amblyopia in Children 3 to <7 Years Old
Brief Summary: The objectives of the Spectacle Phase are:

* In previously untreated pure anisometropic patients (i.e. patients who have not used spectacles in the last year and who do not have strabismus), to determine

  1. the incidence of resolution of amblyopia with spectacle correction alone and
  2. the time course of visual acuity improvement with spectacle correction alone.
* In all other patients, to achieve maximal improvement with spectacle correction prior to entering the randomized trial.

The objectives of the Randomized Trial are:

* To determine whether 5 weeks of patching treatment (2 hours of patching per day of the sound eye combined with at least one concurrent hour of near activities), compared with a control group (using spectacle correction only), improves visual acuity in patients with moderate to severe amblyopia (20/40 to 20/400).
* To determine the maximal improvement and time course of improvement with this patching treatment regimen.


Options:
A: Intervention Type: DEVICE; Name: Eye patch; Assigned to Arm(s): N/A | Intervention Type: DEVICE; Name: Spectacles; Assigned to Arm(s): N/A
B: Intervention Type: DEVICE; Name: Eye patch; Assigned to Arm(s): N/A | Intervention Type: DEVICE; Name: spectacles; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: atropine; Assigned to Arm(s): N/A
C: Intervention Type: DRUG; Name: Atropine; Assigned to Arm(s): N/A
D: Arm Label: Near activities; Type: ACTIVE_COMPARATOR; Interventions: Device: Eye Patch, Procedure: Near activities | Arm Label: Distance activities; Type: ACTIVE_COMPARATOR; Interventions: Device: Eye Patch, Procedure: Distance activities | Intervention Type: DEVICE; Name: Eye Patch; Assigned to Arm(s): Distance activities, Near activities | Intervention Type: PROCEDURE; Name: Near activities; Assigned to Arm(s): Near activities | Intervention Type: PROCEDURE; Name: Distance activities; Assigned to Arm(s): Distance activities

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Insulin Resistance Intervention After Stroke (IRIS) Trial
Brief Summary: The purpose of this study is to determine if pioglitazone is effective in preventing future strokes or heart attacks among non-diabetic persons who have had a recent ischemic stroke.


Options:
A: Arm Label: Behavioral; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: THRIVES | Arm Label: Standard care; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: THRIVES; Assigned to Arm(s): Behavioral
B: Arm Label: Pioglitazone; Type: ACTIVE_COMPARATOR; Interventions: Drug: pioglitazone | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Intervention Type: DRUG; Name: pioglitazone; Assigned to Arm(s): Pioglitazone | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): Placebo
C: Arm Label: 1: Care management; Type: EXPERIMENTAL; Interventions: Behavioral: Care Management | Arm Label: 2: Written Materials; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Written Materials | Intervention Type: BEHAVIORAL; Name: Care Management; Assigned to Arm(s): 1: Care management | Intervention Type: BEHAVIORAL; Name: Written Materials; Assigned to Arm(s): 2: Written Materials
D: Arm Label: Intervention arm; Type: EXPERIMENTAL; Interventions: Behavioral: Instruction in physical training program | Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Instruction in physical training program; Assigned to Arm(s): Intervention arm

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Insulin Resistance Intervention After Stroke (IRIS) Trial
Brief Summary: The purpose of this study is to determine if pioglitazone is effective in preventing future strokes or heart attacks among non-diabetic persons who have had a recent ischemic stroke.


Options:
A: Arm Label: 1 Original Lifestyle; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: DPPOS Group Lifestyle, Behavioral: DPPOS Boost Lifestyle, Behavioral: Intensive Lifestyle Group Session | Arm Label: 2 Original Metformin; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: DPPOS Group Lifestyle, Drug: Metformin, Behavioral: Intensive Lifestyle Group Session | Arm Label: 3 Original Placebo; Type: PLACEBO_COMPARATOR; Interventions: Behavioral: DPPOS Group Lifestyle, Behavioral: Intensive Lifestyle Group Session | Intervention Type: BEHAVIORAL; Name: DPPOS Group Lifestyle; Assigned to Arm(s): 1 Original Lifestyle, 2 Original Metformin, 3 Original Placebo | Intervention Type: DRUG; Name: Metformin; Assigned to Arm(s): 2 Original Metformin | Intervention Type: BEHAVIORAL; Name: DPPOS Boost Lifestyle; Assigned to Arm(s): 1 Original Lifestyle | Intervention Type: BEHAVIORAL; Name: Intensive Lifestyle Group Session; Assigned to Arm(s): 1 Original Lifestyle, 2 Original Metformin, 3 Original Placebo
B: Arm Label: Pioglitazone; Type: EXPERIMENTAL; Interventions: Drug: Pioglitazone | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Pioglitazone; Assigned to Arm(s): Pioglitazone | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
C: Arm Label: Pioglitazone; Type: ACTIVE_COMPARATOR; Interventions: Drug: pioglitazone | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Intervention Type: DRUG; Name: pioglitazone; Assigned to Arm(s): Pioglitazone | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): Placebo
D: Arm Label: Pioglitazone; Type: ACTIVE_COMPARATOR; Interventions: Drug: Pioglitazone study drug, Drug: Pioglitazone Open Label | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo, Drug: Pioglitazone Open Label | Intervention Type: DRUG; Name: Pioglitazone study drug; Assigned to Arm(s): Pioglitazone | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo | Intervention Type: DRUG; Name: Pioglitazone Open Label; Assigned to Arm(s): Pioglitazone, Placebo

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Insulin Resistance Intervention After Stroke (IRIS) Trial
Brief Summary: The purpose of this study is to determine if pioglitazone is effective in preventing future strokes or heart attacks among non-diabetic persons who have had a recent ischemic stroke.


Options:
A: Arm Label: pioglitazone; Type: ACTIVE_COMPARATOR; Interventions: Drug: pioglitazone | Arm Label: rosiglitazone; Type: ACTIVE_COMPARATOR; Interventions: Drug: rosiglitazone | Arm Label: TZD placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Arm Label: Vitamin D; Type: ACTIVE_COMPARATOR; Interventions: Dietary Supplement: Vitamin D | Arm Label: Vitamin D placebo; Type: PLACEBO_COMPARATOR; Interventions: Dietary Supplement: Placebo | Intervention Type: DRUG; Name: pioglitazone; Assigned to Arm(s): pioglitazone | Intervention Type: DRUG; Name: rosiglitazone; Assigned to Arm(s): rosiglitazone | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): TZD placebo | Intervention Type: DIETARY_SUPPLEMENT; Name: Vitamin D; Assigned to Arm(s): Vitamin D | Intervention Type: DIETARY_SUPPLEMENT; Name: Placebo; Assigned to Arm(s): Vitamin D placebo
B: Arm Label: Pioglitazone; Type: ACTIVE_COMPARATOR; Interventions: Drug: pioglitazone | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Intervention Type: DRUG; Name: pioglitazone; Assigned to Arm(s): Pioglitazone | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): Placebo
C: Arm Label: Pioglitazone QD; Type: EXPERIMENTAL; Interventions: Drug: Pioglitazone | Arm Label: Placebo QD; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Pioglitazone; Assigned to Arm(s): Pioglitazone QD | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo QD
D: Arm Label: Aleglitazar; Type: EXPERIMENTAL; Interventions: Drug: Aleglitazar | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Aleglitazar; Assigned to Arm(s): Aleglitazar | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Treatment of Depression Following Bypass Surgery
Brief Summary: The purpose of this study is to treat depression in patients who have undergone coronary artery bypass graft (CABG).


Options:
A: Arm Label: Depressed Intervention; Type: EXPERIMENTAL; Interventions: Behavioral: Psychoeducation; Treatment recommendations, Drug: Pharmacotherapy | Arm Label: Depressed Usual Care; Type: ACTIVE_COMPARATOR; Interventions: Other: Usual Care | Arm Label: Non-Depressed Control Group; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Psychoeducation; Treatment recommendations; Assigned to Arm(s): Depressed Intervention | Intervention Type: DRUG; Name: Pharmacotherapy; Assigned to Arm(s): Depressed Intervention | Intervention Type: OTHER; Name: Usual Care; Assigned to Arm(s): Depressed Usual Care
B: Arm Label: metacognitive therapy plus CR; Type: EXPERIMENTAL; Interventions: Behavioral: Metacognitive Therapy | Arm Label: CR alone (control); Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Cardiac Rehabilitation (treatment as usual) | Intervention Type: BEHAVIORAL; Name: Metacognitive Therapy; Assigned to Arm(s): metacognitive therapy plus CR | Intervention Type: BEHAVIORAL; Name: Cardiac Rehabilitation (treatment as usual); Assigned to Arm(s): CR alone (control)
C: Arm Label: control; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Psycho edcuactional support; Type: EXPERIMENTAL; Interventions: Behavioral: Psychoeducational support | Intervention Type: BEHAVIORAL; Name: Psychoeducational support; Assigned to Arm(s): Psycho edcuactional support
D: Arm Label: Collaborative Care; Type: EXPERIMENTAL; Interventions: Behavioral: Collaborative Care Treatment | Arm Label: Usual Care; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Usual Care Treatment | Intervention Type: BEHAVIORAL; Name: Collaborative Care Treatment; Assigned to Arm(s): Collaborative Care | Intervention Type: BEHAVIORAL; Name: Usual Care Treatment; Assigned to Arm(s): Usual Care

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Treatment of Depression Following Bypass Surgery
Brief Summary: The purpose of this study is to treat depression in patients who have undergone coronary artery bypass graft (CABG).


Options:
A: Intervention Type: BEHAVIORAL; Name: Program to Encourage Active, Rewarding Lives (PEARL); Assigned to Arm(s): N/A
B: Arm Label: Depressed Intervention; Type: EXPERIMENTAL; Interventions: Behavioral: Psychoeducation; Treatment recommendations, Drug: Pharmacotherapy | Arm Label: Depressed Usual Care; Type: ACTIVE_COMPARATOR; Interventions: Other: Usual Care | Arm Label: Non-Depressed Control Group; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Psychoeducation; Treatment recommendations; Assigned to Arm(s): Depressed Intervention | Intervention Type: DRUG; Name: Pharmacotherapy; Assigned to Arm(s): Depressed Intervention | Intervention Type: OTHER; Name: Usual Care; Assigned to Arm(s): Depressed Usual Care
C: Intervention Type: DRUG; Name: Treatment of depression; Assigned to Arm(s): N/A | Intervention Type: BEHAVIORAL; Name: Suicide prevention intervention; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Suicide prevention treatment; Assigned to Arm(s): N/A
D: Intervention Type: BEHAVIORAL; Name: Care manager outreach and monitoring; Assigned to Arm(s): N/A

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Treatment of Depression Following Bypass Surgery
Brief Summary: The purpose of this study is to treat depression in patients who have undergone coronary artery bypass graft (CABG).


Options:
A: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Behavioral: Interactive Voice Response System | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Behavioral: Nurse-Led Group Clinic Visits | Intervention Type: BEHAVIORAL; Name: Interactive Voice Response System; Assigned to Arm(s): 1 | Intervention Type: BEHAVIORAL; Name: Nurse-Led Group Clinic Visits; Assigned to Arm(s): 2
B: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Behavioral: Psychotherapy, Other: Usual cardiological care | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Information session, Other: Usual cardiological care | Intervention Type: BEHAVIORAL; Name: Psychotherapy; Assigned to Arm(s): 1 | Intervention Type: BEHAVIORAL; Name: Information session; Assigned to Arm(s): 2 | Intervention Type: OTHER; Name: Usual cardiological care; Assigned to Arm(s): 1, 2
C: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Behavioral: Cognitive Behavioral Therapy (CBT) | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Usual Care | Intervention Type: BEHAVIORAL; Name: Cognitive Behavioral Therapy (CBT); Assigned to Arm(s): 1 | Intervention Type: BEHAVIORAL; Name: Usual Care; Assigned to Arm(s): 2
D: Arm Label: Depressed Intervention; Type: EXPERIMENTAL; Interventions: Behavioral: Psychoeducation; Treatment recommendations, Drug: Pharmacotherapy | Arm Label: Depressed Usual Care; Type: ACTIVE_COMPARATOR; Interventions: Other: Usual Care | Arm Label: Non-Depressed Control Group; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Psychoeducation; Treatment recommendations; Assigned to Arm(s): Depressed Intervention | Intervention Type: DRUG; Name: Pharmacotherapy; Assigned to Arm(s): Depressed Intervention | Intervention Type: OTHER; Name: Usual Care; Assigned to Arm(s): Depressed Usual Care

Answer: D